D.B. Root & Company LLC Purchases Shares of 1,528 Illumina, Inc. (NASDAQ:ILMN)

D.B. Root & Company LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,528 shares of the life sciences company’s stock, valued at approximately $204,000.

Other hedge funds have also made changes to their positions in the company. Intech Investment Management LLC purchased a new position in shares of Illumina in the 2nd quarter valued at $313,000. Sei Investments Co. boosted its stake in Illumina by 37.3% in the second quarter. Sei Investments Co. now owns 97,681 shares of the life sciences company’s stock valued at $10,196,000 after acquiring an additional 26,538 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Illumina by 97.1% during the second quarter. Thrivent Financial for Lutherans now owns 60,298 shares of the life sciences company’s stock worth $6,294,000 after purchasing an additional 29,709 shares during the last quarter. Gabelli Funds LLC increased its position in shares of Illumina by 27.6% during the second quarter. Gabelli Funds LLC now owns 6,589 shares of the life sciences company’s stock worth $688,000 after purchasing an additional 1,425 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Illumina by 127.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 776 shares of the life sciences company’s stock valued at $81,000 after purchasing an additional 435 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research reports. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Royal Bank of Canada lifted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. Piper Sandler dropped their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $134.76 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The firm has a market capitalization of $21.37 billion, a P/E ratio of -13.53 and a beta of 1.11. The company’s fifty day moving average is $139.06 and its two-hundred day moving average is $134.26.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the firm earned $0.33 earnings per share. The firm’s revenue was down 3.5% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.